Shots:
- The US FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with r/r MZL who have received ≥2L of systemic therapy
- Approval was supported by MZL cohort data from the P-II (TRANSCEND FL) trial assessing Breyanzi in pts with r/r indolent B-cell non-Hodgkin lymphoma incl. follicular lymphoma & MZL
- In Breyanzi-treated pts (3L+) that were included in the primary analysis (n=66), ORR was 95.5%, with 62.1% achieving CR; the mDoR was not reached, with 90.1% responders remaining in response at 24mos.
Ref: BMS | Image: BMS |Press Release
Related News: BMS’ Breyanzi Receives the EC Approval to Treat R/R Mantle Cell Lymphoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
